Solution for i/m injections
Virus titer: 2×106 – 2×108 CPD50/ml
- Pharmacotherapeutic group: immunomodulator, ATC: L03AX,
- API of Rigvir: nonpathogenic ECHO-7 wild type virus strain, adapted to melanoma cells (Picornaviridae genera, Enterovirus genus, ECHO group, type 7),The sequence difference from the wild type virus strain Wallace ~20%,
- Stable virus strain (for 20 years),
- Rigvir can induce temporary side-effects (temperature around 37°C for 1-3 days, fatigue),
- Does not contain any antibiotics, stimulants, or other potentially toxic substances,
- Must be stored at the temperature of -20°C and transported frozen.
- Registered at the State Agency of Medicines of Latvia, 29.04.2004.
Marketing authorisation holder – Ltd Latima, Latvia
Rigvir belongs to the immunomodulator group of medicines. As a viral immunomodulator with antitumour effect, Rigvir is registered for treatment of melanoma, local therapy of cutaneous and subcutaneous metastases, prevention of recurrence and metastases after radical surgery. Rigvir has been used for the following types of tumours:
It is scientifically and practically proven that the following tumour types are sensitive to Rigvir:
- stomach cancer,
- colorectal cancer,
- pancreatic cancer,
- kidney cancer,
- uterine cancer,
- bladder cancer,
- lung cancer,
- prostate cancer,
- sarcoma of several types: lymphosarcoma, angiosarcoma, reticulosarcoma, rabdomiosarcoma.
The direct antitumour effect of Rigvir is associated with oncotropism and oncolysis.
The cytolytic effect of the medicine is selective – applies to malignant cells without affecting normal tissue cells.
It is very essential that Rigvir induces the emergence (expression) of tumour-associated differentiation antigens on the surface of non-lysed malignant cells and suppresses the expression of MAGE antigens which are associated with the progressive growth of melanoma.
Altered in such a way, the surface structures of malignant cells become a target for cytotoxic mechanisms of the immune system.
Rigvir mechanism of anticancer activity in humans:
- Degenerative-distrophic changes of tumor cells (oncolysis).
- Change of cell composition of tumour stroma and intensive lymphoid cell infiltration in the tumour which corresponds to the morphologic view ofimmune rejection.
- Following apoptosis of tumour cells (after several Rigvir courses).
Rigvir discoverer, researcher - Professor, Dr. med. habil. Aina Muceniece
Aina Muceniece (23.03.1924.-14.02.2010.) – Rigvir inventor, Dr.med. (1974), Dr.habil.med. (1992), Honourable Member of Latvian Academy of Sciences (1992), Emeritus Scientist for the problems of immunology, oncology, and virology (1996), Cross of Recognition for special services for the benefit of Latvia (2005). The participation in the work of three scientific associations of oncologists, immunologists, and microbiologists. The Member of two Scientific Boards with the rights to give the scientific name. For 24 years (1965-1989), the supervisor of Cancer Virotherapy Laboratory of August Kirchenstein Institute of Microbiology and Virology, developer of the original immunomodulator of viral nature with anticancer efficacy – Rigvir.